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Abstract
Background: Type 2 diabetes (T2DM) is the leading cause of chronic kidney disease (CKD) in western countries.
The combination of both increases the risk of end stage renal disease (ESRD), cardiovascular events and all-cause
mortality. Early control of blood pressure (BP) and proteinuria (Pu) is crucial to slow down the progression of the
CKD and prevent cardiovascular events and mortality. The primary objective of the study was to assess BP and Pu
control after a 2-year follow-up in T2DM patients with CKD.
Methods: Prospective, multicenter, observational study. Overall, 153 French nephrologists included 986 T2DM patients
with Pu (≥0.5 g/day) and an eGFR >15 ml/min/1.73 m2. Data from 729 patients were available after a 2-year follow-up.
BP and Pu control were respectively defined as less than 140/90 mmHg and 0.5 g/day. We also looked at renal and
cardiovascular events.
Results: At baseline, 74 % of the patients were male, mean age was 70 years. The mean T2DM duration was 17 years
with a mean HbA1c of 7.4 %. All were treated for hypertension and 33 % had a controlled BP; 81 % had dyslipidemia
and LDLc was <1 g/L for 54 %; 44 % had retinopathy, 40 % macrovascular complications and 12 % heart failure. Mean
Pu was 2 g/day and eGFR 40 ± 20 mL/min/1.73 m2, with 13, 18, 32 and 37 % of the patients in respectively stage 2, 3a,
3b and 4 CKD.
After two years, 21 % reached the Pu target and 39 % the BP target. The mean eGFR of 40 ± 20.3 ml/min/1.73 m2 at
baseline dropped to 33.9 ± 22.6 ml/min/1.73 m2 by year two (p < 0.001). This corresponded to a mean annual eGFR
reduction of 3.2 ml/min/1.73 m2. 118 patients presented a renal event (16.2 %): doubling of serum creatinine for 86
patients (11.8 %) and start of dialysis for 72 (9.9 %); 176 patients (24.1 %) developed at least one cardiovascular
complication (mainly coronary events and acute heart failure) during the follow-up period, and among these,
50 had also developed renal complications. Sixty patients died, i.e., 8.2 %, 26 patients from cardiovascular causes.
Conclusion: Our study highlights that achieving BP and Pu targets remains a major challenge in patients with
T2DM and nephropathy. Renal failure emerges as a more frequent event than death.
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Background
Type 2 diabetes mellitus (T2DM) is a chronic progressive
disease affecting over 370 million patients worldwide in
2012 [1]. In France, the prevalence of T2DM has been es-
timated to be around 5.5 % in 2012 and this figure is con-
stantly rising as obesity and ageing of the population
progress [2]. Diabetes-related complications are less fre-
quent today than 20 years ago and this is mainly due to a
better management of cardiovascular (CV) risk factors
and improved glucose control [3]. While the largest de-
cline was seen in rate of myocardial infarction (MI), the
smallest reduction has been observed for end-stage renal
disease (ESRD) and T2DM remains the leading cause of
chronic kidney disease (CKD) in western countries [4]
with a prevalence of 25 to 50 % worldwide [5–8] and al-
most 25 to 30 % in France [4, 9]. Data from a recently
published French registry showed that ESRD related to
T2DM increased from 2007 to 2011 with an absolute
change of 21 %, only partially attributed to population age-
ing and increased prevalence of T2DM [9].
The combination of T2DM and CKD not only in-
creases the risk of ESRD but also of CV events and all-
cause mortality, with CV complications being the main
cause of death in these patients [10]. Recently it has
been shown that the risk of both MI and all-cause death
in people with T2DM and CKD were similar to or higher
than those in people with history of MI [11].
Two large cohorts have described the natural history
of T2DM-associated nephropathy: the British UKPDS
and the Steno center’s Danish study [12, 13]. Both stud-
ies showed that the development of nephropathy led to
an increased risk of death, especially due to CV causes,
and that the risk of death was also higher than the risk
of renal disease progression.
Early detection and management of these patients are
crucial and involve a close monitoring of CV risk fac-
tors, control of blood pressure (BP) and proteinuria (Pu)
and use of drugs acting on the renin angiotensin system
(RAS) to slow down the progression of the renal disease
and prevent CV events and mortality [14–17]. Some de-
bate remains as to the BP target to obtain: historically
<130/80 mmHg [18], or more recently <140/85 mmHg
[19], <140/80 mmHg [20] or <140/90 mmHg [21–23]. It
is widely accepted that Pu should be decreased under
0.5 g/day [18].
Nevertheless, few real-life prospective studies report the
proportion of T2DM patients with hypertension and Pu in
whom the BP and Pu goals have been achieved and of the
incidence of renal and CV events. In this context, we
conducted the ALICE- PROTECT observational study.
Methods
This is the final analysis of the 2-year follow-up of the
French ALICE-PROTECT cohort which was a multicenter,
observational, prospective study. Details of the cohort cre-
ation, the included patients and the data recorded are de-
scribed elsewhere [24]. Briefly, adult outpatients with
T2DM, clinical Pu [defined by 24-h Pu ≥ 0.5 g per day or
urinary protein/creatinine ratio (UPCR) ≥ 50 mg/mmol
(≥500 mg/g) or urinary albumin/creatinine ratio ≥ 30 mg/
mmol (≥ 300 mg/g)] and an estimated glomerular filtration
rate (eGFR by MDRD formula) over 15 mL/min/1.73 m2
were recruited by 153 active nephrologists throughout
France between January 2010 and February 2011. The
planned follow-up for the whole population was
2 years, up to June 2013, with one planned visit per
year ± 4 months. No specific assessment was requested for
the study.
Assessments
The main goal of the ALICE-protect study was to evalu-
ate the percentage of patients with T2DM and nephrop-
athy reaching BP (< 130/80 mmHg) and Pu (< 0.5 g/day)
targets after a 2-year follow-up in real-life conditions.
Given that some European and French recommenda-
tions [19, 22] for the BP target to reach for T2DM pa-
tients or those with CKD changed during the course of
the study, the same evaluation was also carried out using
the threshold of BP < 140/90 mmHg.
Secondary endpoints were the occurrence of renal
(doubling of serum creatinine and/or end- stage renal dis-
ease) and CV (acute coronary syndrome, stroke, amputa-
tion, hospitalization for heart failure, carotid, coronary and
lower limb arteries revascularization) complications in
real-life conditions. We also looked at the predictive factors
for complications and reaching the BP and Pu goals.
Data analysis-statistics
The statistical analysis plan was defined before the start of
the analysis. Descriptive statistics of recruited patient char-
acteristics were performed. Quantitative variables were de-
scribed in terms of mean, standard deviation, median and
outliers, and qualitative variables in terms of absolute fre-
quency and percentage per modality. Depending on the
nature of the variables (continuous or discrete) and data
availability, t-tests or Wilcoxon tests and chi-squared or
Fisher’s exact tests were carried out. To evaluate the statis-
tical significance of changes to continuous parameters over
time, Wilcoxon signed-rank tests were also adjusted.
Multivariate models were also used to determine the
predictive factors for BP and Pu control and incidence
of CV and renal events. For each event of interest, the
relationship with potentially related factors was evalu-
ated using univariate analysis, and then the significant
factors at a threshold of p < 0.10 were entered into a lo-
gistic regression using a stepwise method and a mainten-
ance threshold in the model set at p < 0.05. The factors
included in the final model are described in the results
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with the Odds-Ratio (OR), their 95 % confidence interval
(CI), and their p-values.
Three analyses were performed: data analysis of the
initial questionnaire and the general questionnaire for
nephrologists; analysis after the 1-year database lock;
and then after the 2 year follow-up.
All statistical analyses were performed using SAS 9.3 soft-
ware (SAS Institute, Cary, NC, USA). Details about sam-
ple size calculation have been published elsewhere [24].
Results
Demographic and disease characteristics of the
population at baseline
Nine hundred eighty-six patients were recruited and
analysed at baseline [24]. Of these, 630 patients were
followed for 2 years (mean follow-up 23 ± 2.4 months)
with clinical and biological data available.
These patients therefore constitute the analysed popu-
lation for the study’s primary objective (BP and Pu con-
trol after a 2-year follow-up). The occurrence of CV or
renal events was analysed in this population as well as in
those patients who had died during the study or had
been lost to follow-up by year two but who had experi-
enced complications during the first year, i.e., 729 pa-
tients (cf. numbers in bold in Fig. 1).
Patients characteristics (n = 729) were not different
from those described in the 986 analysed at baseline:
mean age was 69 years with 31 % of the patients over
75 years, 74 % were male, mean body mass index (BMI)
was 30 kg/m2 and most patients had a long history of
diabetes (mean duration of 17 years). The mean HbA1c
was 7.4 %: 43 % of the patients had an HbA1c <7 % and
25 % had an HbA1c ≥8 %. Essentially all received an anti-
diabetic treatment (98 %), mostly insulin alone or com-
bined with oral antidiabetic agents (Table 1). Nearly all
patients had at least two associated CV risk factors: all
had hypertension (mean office BP was 149 ± 20 / 79 ±
11 mmHg 33 % with controlled BP i.e., < 140/90 mmHg),
10 % were active smokers, 81 % had dyslipidemia. Details
on antihypertensive and statin treatments are presented in
Table 1. Most patients received antihypertensive treat-
ments (99.3 %) and 75 % were treated with three antihy-
pertensive agents or more.
As required by the inclusion criteria, all patients had
nephropathy. Other diabetic complications, were highly
prevalent driven by retinopathy (44 %), macrovascular
complications (40 %, mainly coronary heart disease for
27 % of the patients), and symptomatic heart failure
(12 %). Mean eGFR was 40 mL/min/1,73 m2: 37 % of
the patients had stage 4 CKD (eGFR < 30 mL/min/
1,73 m2), 50 % had stage 3 CKD (eGFR 30–60 mL/min/
1,73 m2), 10 % stage 2 CKD (eGFR 60–90 mL/min/
1,73 m2), and 3 % had normal eGFR. The mean Pu was
1.9 ± 1.7 g/day (median 1.3 g/day, 25–75 % quartiles
[0.8; 2.3]), 34 % of the patients had Pu between 0.5 and
1 g/day or an UPCR between 0.5 and 1 g/g, 48 % be-
tween 1 and 3 g/day ou g/g and 18 % above 3 g/day ou
g/g (Fig. 2). Overall, 91.5 % of the patients were on RAS
blockers [angiotensin conversion enzyme inhibitors
(ACEi), angiotensin receptor blockers (ARB) or direct
renin inhibitor (DRI)]: 70 % with only one and 21.5 %
with two.
The 257 patients lost to follow-up were similar at
baseline from the above population of 729 patients: the
sex ratio was the same, as was the mean age and dur-
ation of diabetes. They presented with similar CV risk
factors and diabetes-related complications, with the
only exception being a slightly lower incidence of retin-
opathy (37 % compared to 44 %, p = 0.053). Although
their Pu rates were similar, they had slightly higher
eGFR values (44.5 vs 40 ml/min/1.73 m2, p = 0.018).
The treatments they were receiving were not overly
Fig. 1 Disposition of the patients
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different, notably with a similar proportion of pa-
tients with RAS blockers (around 91 %), although
dual RAS blockade was more frequent in the patients
who were lost to follow-up (28.8 % compared to
21.5 %, p = 0.017).
Blood pressure and proteinuria control after 2 years
The dual objective of BP < 130/80 mmHg and Pu < 0.5 g/d
or UPCR < 0.5 g/g was achieved for 25 patients (4.5 %) out
of the 558 patients in whom the BP and Pu values (24-h
measurement or UPCR) were available at 2 years.
As mentioned in the methods section, the same evalu-
ation was carried out using the threshold of BP < 140/
90 mmHg: 62 patients (11.1 %) achieved the dual
objective.
Blood pressure
Mean systolic BP (SBP) decreased significantly from
148.5 ± 20.5 mmHg at baseline to 144 ± 19.7 mmHg at
year two, given an average reduction of 4.5 ± 22.9 mmHg
(p < 0.001). A similar change was observed in average
diastolic blood pressure (DBP) (78.8 ± 11.3 mmHg at
baseline), with a significant reduction of 2.8 ± 12.9 mmHg
at year two (p < 0.001). After the 2-year follow-up period,
14.3 % of patients had a BP < 130/80 mmHg and 38.8 %
had a BP < 140/90 mmHg. Home BP monitoring (HBPM)
or ambulatory BP monitoring (ABPM) values were
Table 1 Treatments at baseline and at year 2
Baseline
N = 729
Visit at year 2
N = 688
Antidiabetic treatment (% of the treated patients)
Insulin ± OADa 62.5 72.3
OAD only 37.5 27.7
Antihypertensive treatment (% of the treated patients)




Diuretics (at least one) 77.1 80.4





Central acting agents and others 25.7 27.4
Other treatments (% of the patients)
Statins 76.4 69.6
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Fig. 2 Change in Pu stage at the end of the study based on the Pu stage recorded at baseline
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reported for only 8.6 and 1.3 % of the followed patients
respectively.
The number of patients who didn’t receive any antihy-
pertensive treatment increased from 0.7 % at baseline to
9.7 % after 2 years. The number of patients receiving a
four-drug therapy or more decreased from 46 % at base-
line to 39 % after 2 years. Overall, antihypertensive treat-
ment score remained constant in 39 % and decreased in
34 % of the patients with uncontrolled BP at year two.
At year 2, the different antihypertensive classes used
were similar to those at baseline (Table 1). Different di-
uretics were combined in 14.6 % of the diuretic treated
patients at the end of the study.
Controlled BP at baseline, the lowest Pu rate at year
two and the absence of diuretic treatment at year two
were significant factors associated with reaching the BP
target of < 140/90 mmHg in the multivariate analysis
(Fig. 4a).
Proteinuria
Pu was reported by using 24-h urine measurement in
384 patients, by an UPCR in 202 patients, and by Pu
concentration alone in 99 patients. The changes over
time were evaluable in 522 patients either by 24-h Pu
readings or UPCR.
The mean 24-h Pu and UPCR remained stable through-
out the study at 1.9 ± 1.7 g/day and 2.0 ± 2.6 g/g respect-
ively (measurement at the end of the study). At the end of
the study, 20 % of patients had reached the Pu target (24-
h quantitation or UPCR) of < 0.5 g/day or g/g, 21 % had
Pu between 0.5 and 1 g/day or UPCR between 0.5 and
1 g/g, 38%between 1 and 3 g/day or UPCR between 1 and
3 g/g and 21 % of patients had nephrotic range Pu. This
latter group was mainly composed of patients who had
nephrotic range Pu at baseline, however a marked increase
of Pu, from < 1 g/day to > 3 g/day was observed in 2.6 % of
the patients overall (Fig. 2).
The number of patients receiving at least one RAS
blocker (ARBs and/or ACEi and/or DRI) fell during the
course of the study, from 91.5 % of patients at baseline
to 78.1 % at year two. Among these patients, single RAS
blockade was the most common: 76.5 % at baseline and
80 % at year two. Dual RAS blockade was prescribed for
23 % of patients at baseline and 20 % at year two; the
use of triple RAS blockade was marginal, concerning
three patients at baseline and none by the end of the
study. The preferred combination was an ARB and an
ACEi, and this trend was even more marked at the end
of the study, as the proportion of ACEi + ARB combina-
tions used in patients receiving a dual RAS blockade
rose from 69.5 % at baseline to 87 % by year two. Among
the patients who were receiving a single RAS blocker at
baseline, at year two most remained with a single RAS
blockade (72 %), less than 9 % received a dual RAS
blockade, and almost 20 % were not receiving any RAS
blocking agents. Among the patients who were receiving
a dual RAS blocker at baseline, at year two 45 % were
still on this dual blockade, 40 % were given a single RAS
blocker, and 15 % were no longer receiving any RAS
blockers.
Pu levels after the 2-year follow-up had a moderate
impact on the prescribed RAS blocker treatment. There-
fore, in patients with a Pu > 1 g/day or an UPCR > 1 g/g,
20 % were not receiving any RAS blockers at year two,
61 % were receiving a single blockade, and 19 % a dual
blockade. These proportions were 17, 72 and 11 % re-
spectively for patients with a Pu < 1 g/day or an UPCR
< 1 g/g at year two.
Controlled BP at year two, lowest baseline Pu values,
antialdosterone treatment at year two and the absence of
centrally acting antihypertensive drugs at baseline were
significant factors associated with reaching the Pu target
in the multivariate analysis (Fig. 4b). We didn’t observe
any correlation with the use of single or dual RAS
blockade.
Metabolic parameters
HbA1C values were available for 504 patients at the end
of the study. Glycemic control was overall stable after a
2-year follow-up (mean HbA1C 7.3 ± 1.2 %) with 37.7 %
of the patients with HbA1C < 7 %, 38.1 % between 7 and
8 % and 24.2 % of patients above 8 %. At year two, 11 %
of the patients were no longer receiving any antidiabetic
treatment (vs 2 % at baseline).
LDL-cholesterol (LDL-c) values were reported for 326
patients after the 2-year follow-up and 64 % of them had
a LDL-c value < 1 g/L.
Renal events and eGFR decrease
During follow-up, 118 patients suffered from deterior-
ation in renal function (16.2 %): doubling of serum cre-
atinine for 86 patients (11.8 %) and/or start of dialysis
treatment for 72 (9.9 %). None of the patients was trans-
planted. The incidence of these renal complications was
higher in patients who had a medical history of CV dis-
ease at baseline (18.6 % of patients compared to 14.3 %
with no history of CV disease at baseline). We also ob-
served a correlation between deterioration of renal func-
tion, Pu rate and SBP levels at baseline (Fig. 3). In
multivariate analysis the only predictors for the occur-
rence of renal complications were a higher Pu at base-
line and the absence of treatment by one or two RAS
blockers at year two, with no correlation observed with
HbA1c level (Fig. 4c).
The mean eGFR of 40 ± 20.3 ml/min/1.73 m2 at base-
line dropped to 36.5 ± 20.9 by year one and to 33.9 ±
22.6 ml/min/1.73 m2 by year two (p <0.001). This corre-
sponds to a mean annual eGFR reduction of 3.2 ml/min/
Halimi et al. BMC Nephrology  (2016) 17:135 Page 5 of 10
1.73 m2. The relative annual loss of renal function was
4.3 % for patients in stage 1 CKD, 8 % in stage 2, 7.2 %
in stage 3a, 8.5 % in stage 3b and reached 11.3 % in stage
4. The GFR slope differed according to both the Pu and
the BP level at baseline. The higher the Pu at baseline,
the more marked was the decline in renal function:
5.3 % when Pu was between 0.5 and 1 g/day, 7.9 % when
Pu was between 1 and 3 g/d and 13 % for Pu higher than
3 g/d. Similarly, the decline in renal function was more
marked when BP was uncontrolled (> 140/90 mmHg) at
baseline, 9.5 % versus 5.5 % when BP was controlled.
This was despite the fact that the mean eGFR at baseline
was similar in all these groups.
Cardiovascular events and death
Out of the 729 patients for whom we had follow-up data
at year two, 60 had died, i.e., 8.2 %: 23 during year one
and 37 during year two. Twenty-six patients died from
CV causes, 16 from another cause of death (no details
available), and 18 from unknown causes. The baseline
demographic and clinical data for these 60 patients did
not differ greatly from the total population analysed at
baseline (n = 986): they had a mean age of 74 years, an
average eGFR of 37 ml/min/1.73 m2, 35 % of them suf-
fered from severe renal failure and 53 % had a history of
macrovascular complications.
One hundred seventy-six patients (24.1 %) developed
at least one CV complication during the follow-up
period, and among these, 50 also developed renal com-
plications (doubling of serum creatinine and/or ESRD).
Overall, 61 patients (8.4 %) had a coronary event (acute
coronary syndrome and/or coronary revascularisation),
25 patients (3.4 %) had a stroke, 32 patients (4.4 %)
underwent a lower limb revascularisation procedure, 17
patients (2.3 %) required amputation and 80 patients
(11 %) were hospitalised for acute heart failure. The risk
of developing such complications was twice as high
among patients who had a medical history of CV com-
plications at baseline (data not shown).
Among the patients who were free from CV complica-
tions at baseline (n = 412), the incidence of CV compli-
cations during the follow-up period increased in line
with the severity of the CKD. For example, coronary
heart disease was observed in 2.9 % of patients with an
initial eGFR ≥ 60 ml/min/1.73 m2, 5.6 % in those with an
eGFR between 30 and 60 ml/min/1.73 m2, and 7.5 % in
those with an eGFR < 30 ml/min/1.73 m2. The incidence
of heart failure requiring hospitalisation was 2.9, 6.2 and
10.2 % for these patient groups respectively and 5.7, 9.2
and 15 % for macrovascular complications (coronary
heart disease, peripheral arterial disease, and stroke).
In multivariate analysis, the predictors of CV complica-
tions occurrence were a medical history of stroke, history
of peripheral arterial disease in the lower extremities, sleep
apnoea treated with continuous positive airway pressure
(CPAP) at baseline, a lack of treatment with RAS blockers
at year two, a higher antihypertensive treatment score and
severe CKD at year two (Fig. 4d).
Discussion
This large real-life study of patients with T2DM and
CKD confirmed that BP and Pu targets remain a major
Fig. 3 Renal complications * after a two year follow-up according to Pu and SBP levels at baseline
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Fig. 4 Associated factors with BP and Pu control and cardiovascular and renal events occurrence. a Associated factors BP <140/90 mmHg at year 2.
The following parameters (significant in univariate analysis) were included in the model : smoking status, BP control at baseline, antihypertensive score
at baseline and at year 2, prescription of CCB, diuretics, antialdosterone or centrally acting drugs at baseline and at year 2, Pu level and severity of renal
failure at year 2, diabetes control and history of retinopathy at baseline. b Associated factors with Pu < 0,5 g/day at year 2. The following parameters
(significant in univariate analysis) were included in the model : age, BP control at year 2, Pu level and severity of renal failure at baseline, prescription of
antialdosterone or centrally acting drugs treatment at baseline and year two. c Associated factors with renal events at year 2. The following parameters
(significant in univariate analysis) were included in the model : BP control at baseline, Pu level and severity of renal failure at baseline and at year 2, the
antihypertensive treatment score at year two, RAS blockade at baseline and year 2, prescription of CCB, diuretics, centrally acting drugs or statins at
baseline and at year 2. d Associated factors with cardiovascular events at year 2. The following parameters (significant in univariate analysis) were
included in the model : age, duration of hypertension and diabetes, CPAP-treated sleep apnoea, severity of renal failure at baseline and year 2, LDL
cholesterol control at baseline, antihypertensive treatment score at baseline, RAS blockade at year 2, prescription of antiplatelet drugs, CCB, diuretics,
betablockers or centrally acting drugs at baseline and at year 2, history of CV disease at baseline (coronary heart disease, history of stroke, peripheral
arterial disease of the lower extremities, or hospitalisation for heart failure)
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challenge with only 11 % of the patients with BP < 140/
90 mmHg and UPCR < 0.5 g/g after a 2-year follow-up.
Furthermore the renal events rate was higher than the
death rate.
BP control
Less than 40 % of our patients had BP < 140/90 mmHg
at the end of the2-year follow-up despite the use of 3 or
more antihypertensive agents for 75 % of the patients at
baseline, in line with what is usually reported in patients
with impaired renal function [25]. Overall this lack of BP
control could be explained by patient’s poor compliance,
insufficient doses of diuretics, use of concomitant medi-
cations increasing BP, excessive salt intake, etc… [25] It
is also well-known that BP control is more difficult as
renal function worsens. Therapeutic inertia has also
been found to play a role as described by Desai and al
[26]. This retrospective study conducted in hypertensive
patients with CKD showed that true therapeutic inertia
accounted for 44 % of the patients who remained hy-
pertensive while in the other 56 %, physicians either
changed the medication regimen or documented clear
reasons not to change the treatment or tried to change
it. In our study, therapeutic inertia could be one of the
explanations for the relatively high proportion of pa-
tients who remained hypertensive: over one third of the
patients had a reduced treatment score irrespective of
BP control at year 2.
However, these results must be interpreted with caution
as BP was mainly monitored by office- based measure-
ment, which has been demonstrated to be insufficient to
classify CKD patients with hypertension [27]. In our study,
HBPM or ABPM values were reported for less than 10 %
of the patients despite relatively strong data demonstrating
that in patients with CKD, BP measured at home is a bet-
ter predictor of ESRD and CV events than BP measured
in the office [28, 29].
Pu control
In the same way, only 20 % of the patients followed in
our study reached the Pu target after a 2-year follow-up.
It has been largely demonstrated that on top of BP con-
trol, Pu control is also key to slow renal disease progres-
sion [30, 31]. This was also observed in our study, as we
saw a correlation between deterioration in renal function
and persistently high Pu rates and uncontrolled SBP.
Unfortunately, we cannot compare our result with other
large-scale “renal morbidity and mortality” interven-
tional studies of diabetic patients with CKD and protein-
uria as Pu targets are not reported as such [15, 32–34].
Considering the importance of Pu control, it is dis-
appointing to note that changes over time in Pu
were evaluable in only 72 % of the followed patients,
either because the nephrologists did not report any
measurement at the follow-up visit or because the
Pu was only reported in concentration unrelated to
24-h urines or urinary creatinine.
Use of RAS blockers
RAS blockers have proven to be effective in reducing Pu
and slowing CKD progression beyond BP decrease in
T2DM patients [15, 33] and are therefore recommended
for all patients with T2DM and CKD [35].
However, the residual renal risk remains high and spe-
cific studies have been conducted to test the hypothesis of
a better protection with a dual RAS blockade. In relatively
short-term initial studies Pu control has been shown to be
better with a dual RAS blockade than with a single agent
[17, 36]. Unfortunately, more recently two long-term con-
trolled studies (ALTITUDE & VA-NEPHRON) involving
patients with T2DM and CKD reported that even if dual
RAS blockade decreased Pu, not only did this not translate
into any advantage in terms of CV and/or renal morbidity
but it also led to an increase in renal complications
(acute renal failure and hyperkaliemia) [32, 34]. The
findings of ALTITUDE (conducted with the DRI aliski-
ren in dual RAS blockade) led the European Medicines
Agency (EMA) to change aliskiren’ label introducing a
contraindication for its use in patients with diabetes or
renal failure in combination with ACEi or ARBs at the
beginning of 2012. Given that the risk of adverse events
from a dual RAS blockade exists independently of alis-
kiren use [32, 37, 38], the recent Pharmacovigilance
Risk Assessment Committee recommendations on the
EMA website have also drawn prescribers’ attention to
the risk of adverse events in patients receiving a dual
RAS blockade. Thus the labelling for all RAS blockers
is progressively changing. At baseline, 23 % of our pa-
tients were on a dual RAS blockade, and in spite of
changes in recommendations following ALTITUDE
publication [34], a full 20 % were taking two RAS
blockers after the 2-year follow-up, although aliskiren-
based dual blockades had considerably decreased.
The proven efficacy of RAS blockade in T2DM and
CKD patients explains why over 90 % of our patients were
receiving at least one RAS blocker at baseline. What is
more surprising is that about 20 % of patients were no
longer receiving any RAS blockers after the 2-year follow-
up, including those who still had high Pu values, and 20 %
received a dual blockade. Similarly, a study conducted in
US veterans with CKD found that the rate of ARBs/ACEi
discontinuation was also high: less than 10 % of the pa-
tients remained on treatment throughout the whole all
follow-up period [39]. The design of our study does not
allow us to speculate about the reasons for discontinuing
RAS blockers; for e.g., we do not have any information
about the occurrence of severe hyperkaliemia or acute
renal failure during the follow-up.
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Renal events and death
In our study CV events were frequent (12.1 % per year)
and renal disease progression (8.5 % per year) was twice
as high as the risk of death (4.3 % per year). Conversely,
in several studies conducted in patients with CKD from
all causes [40] as well as in diabetic patients with CKD
[12], death was more than twice as likely as renal disease
progression. This difference could be explained by im-
provements in the management and treatment of pa-
tients at high CV risk over the last 20 years.
As expected, the mortality rate in our study is higher
than that reported in the Framingham study for diabetic
patients during the period 1976–2001 (1.58 % per year),
because of concomitant CKD [41]. However, it is lower
than the mortality rate observed in the historical interven-
tional studies IDNT and RENAAL (respectively 6 and
6.8 % per year). One might have thought that mortality
would have been higher in a real life study, but once again
this finding could be due to changes in management of
these patients in the last 15 years [12, 15, 33]. The rate of
renal events in our study exceeded those noted in the
placebo arm of ALTITUDE [34] (2.1 % per year), probably
because the mean eGFR at baseline was lower (40 vs
57 mL/min/1.73 m2) but also perhaps because involve-
ment of patients in clinical trials modify disease progres-
sion maybe related to changes in physicians’ practice and/
or patient compliance [42].
Strengths and limitations
This analysis reports real life data and follow-up on a
relatively large sample of a population with T2DM and
advanced CKD for whom we have little information.
The inclusion criteria in our study did not allow us to
study the natural history of CKD from microalbuminuria
to ESRD. One of the main limitations of the study is that
26 % of the originally enrolled and analysed patients
were lost to follow-up at the end of year two but this is
one of the known drawbacks of a real life study. Sec-
ondly, the data collected are purely observational and
subject to declaration bias. Furthermore, as some results
are lacking, we were not able to explore all parameters
for all followed patients. However data in real-life setting
may have broader applicability versus that from clinical
trials with restrictive inclusion/exclusion criteria and
strict monitoring of the practice.
Conclusions
Our study highlights that achieving BP and Pu targets re-
mains a major challenge in patients with T2DM and ne-
phropathy in clinical practice, even when they are
managed by nephrologists. Furthermore, our study shows
that cardiovascular events and renal disease progression
are more frequent than death unlike what has been ob-
served in previous cohorts.
Our data also suggest that there is room for improve-
ment especially in terms of standardization of BP moni-
toring by using ambulatory methods, treatment regimen
and of Pu measurement.
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